Reboxetine combination therapy with Fluoxetine in the treatment of moderate to severe obsessive-compulsive disorder: A randomized double blind and placebo controlled clinical trial
Latest Information Update: 21 Jul 2023
At a glance
- Drugs Reboxetine (Primary) ; Fluoxetine
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- 18 Jul 2023 Primary endpoint has been met.
- 18 Jul 2023 Status changed from not yet recruiting to completed.
- 18 Jul 2023 Results of Reboxetine in combination with Fluoxetine for the treatment of Obsessive-Compulsive Disorder were published in the Clinical Neuropharmacology